Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 3/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | DGAT2 | Q96PD7 | 7/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 2/20 | 0.31 |
| ▸ | AXL | P30530 | 2/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.31 |
| ▸ | MERTK | Q12866 | 2/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4844554 | 0.90 | CNR1 (0.35) | CNR1CNR2MAPK8LMNAMET | |
| SCHEMBL4013149 | 0.89 | MAPK14 (0.40) | CNR1METAXLTYRO3MERTK | |
| SCHEMBL14018946 | 0.85 | SCN9A (0.34) | SCN9AMAPK8LMNADGAT2PDE2A | |
| SCHEMBL4833086 | 0.85 | SCN9A (0.34) | SCN9AMAPK8LMNADGAT2PDE2A | |
| SCHEMBL4842430 | 0.81 | MAPK14 (0.41) | CNR1MAPK8GSK3B | |
| SCHEMBL4841759 | 0.80 | PTGS2 (0.34) | SCN9ACNR1CNR2DGAT2PDE2A | |
| SCHEMBL4842631 | 0.77 | L3MBTL1 (0.34) | SCN9ALMNADGAT2PDE2APDE10A | |
| SCHEMBL4840788 | 0.77 | MAPK14 (0.39) | METAXLTYRO3MERTK | |
| SCHEMBL4833006 | 0.77 | MAPK14 (0.43) | MAPK8METAXLTYRO3MERTK | |
| SCHEMBL14018790 | 0.76 | MAPK14 (0.33) | MAPK8LMNAMETAXLTYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | claimed |
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | MAP3K1, MAPK1, MAP3K8 | SCN9A 4259/4885FPR2 397/4885CNR1 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.